Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
Get in-depth analysis of the COVID-19 impact on the Drug Discovery Services Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Drug Discovery Services Market
Request For Special PricingThe global drug discovery services market is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1% from 2020 to 2025. The emerging economies, such as India, China, and Brazil, are expected to provide a wide range of opportunities for players in the industry. Furthermore, growth in the biologics market and patent expiries will also boost the growth of this market.
“Medicinal chemistry services accounted for the largest market share in 2019.”
The medicinal chemistry services segment dominated this market in 2019. This segment is expected to have the highest growth as well. The growth of this segment can be attributed to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.
“Oncology therapeutic area to dominate the drug discovery services market in2019.”
In 2019, oncology therapeutic areas segment accounted for the largest market share in market as the number of patients who have cancer is on the rise, the subsequent increase in the demand for effective cancer therapies and the increasing R&D expenditure by pharmaceutical companies in this therapeutic area is fueling the growth of this segment.
“Asia Pacific to grow at the highest rate during the forecast period (2020–2025)”
The drug discovery services market in Asia Pacific is expected to grow at a high pace in the coming years. The factors are attributing to the high growth of the Asia Pacific region, the rapid growth in the pharmaceutical and biopharmaceutical industry, growing number of CROs, and the presence of less-stringent regulations for drug discovery processes and smooth export protocols. However, the North American and European markets will account for a large share due to mature economies and the presence of significant players in the region.
Key Market Players
The major players operating in the market are Laboratory Corporation of America Holdings (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Thermo Fisher Scientific, Inc. (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), and Selvita S.A. (Poland) among others.
Major companies such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International, Inc. (US) have a robust services portfolio. These companies have established drug discovery services with a robust offering that has a prominent presence in the market. Coupled with the global distribution network and partnerships, which exist for these players, they will have a leading share in the market during the forecast period.
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for Years |
2018–2025 |
|
Base Year Considered |
2018 |
|
Forecast Period |
2020–2025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Process, type, drug type, therapeutic area, company type, and region |
|
Geographies Covered |
North America (US, and Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World |
|
Companies Covered |
Key 20 players covered, include Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Jubilant Life Sciences (India), Laboratory Corporation of America Holdings (US), Piramal Enterprises Ltd. (India), Viva Biotech (China), Domainex (UK), Shanghai Medicilon, Inc. (China), TCG Lifesciences Pvt. Limited (India), Frontage Holdings (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), ChemPartner Co., Ltd (China), Aurigene Discovery Technologies Limited (A subsidiary of Dr. Reddy’s, Laboratories) (India), Selvita S.A. (Poland). |
This research report categorizes the market into the following segments:
Drug discovery services Market, by Process
- Target Selection
- Target Validation
- Hit-To-Lead Identification
- Lead Optimization
- Candidate Validation
Drug discovery services Market, By Type
- Medicinal Chemistry Services
- Biology Services
- Drug Metabolism and Pharmacokinetics (DMPK)
- Market, by Drug Type
- Small- molecule Drugs
- Biologic Drugs
Drug discovery services Market, By Therapeutic Area
- Oncology
- Neurology
- Infectious and Immune System Diseases
- Digestive System Diseases
- Cardiovascular Diseases
- Other Therapeutic Areas
Drug discovery services Market, by Company Type
- Tier 1 Pharmaceutical Companies
- Tier 2 Pharmaceutical Companies
- Tier 3 Pharmaceutical Companies
Drug discovery services Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
Recent Developments:
- In 2019, Charles River (US) and CHDI Foundation, Inc. (US), Extended collaboration on drug discovery and development for Huntington’s Disease by five years
- In 2019, Laboratory Corporation of America Holdings’s (US) opened the Covance Drug Development segment opened a new R&D Center in Shanghai, China—its largest facility in the Asia Pacific. This will help the company to grow its business in China and the APAC.
Key Questions Addressed in the Report:
- What are the growth opportunities in the market across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of drug discovery services. Will this scenario continue during the next five years?
- What are the various drug discovery services and their respective market shares in the overall market?
- What are the new trends and advancements in the market?
Frequently Asked Questions (FAQ):
Which is the leading therapeutic area of drug discovery service?
The global drug discovery services market is segmented broadly into Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases and Other Therapeutic Areas. In 2019, oncology drug discovery services commanded the largest share of drug discovery service market. This is primarily attributed to factors such as the High and Growing Number of Research Studies on Cancer Therapeutics, increasing number of patients who have cancer, the subsequent increase in the demand for effective cancer therapies and the increasing R&D expenditure by pharmaceutical companies in this therapeutic area. These factors have resulted in an increase in outsourcing of drug discovery services, which positively impacts the oncology drug discovery services market.
Which is the leading drug type for drug discovery services?
The drug discovery services market by drug type is segmented into small molecule drugs and biologics. In 2019, small molecule drugs accounted for the largest share of the drug discovery services market by drug type. The large share of this segment is attributed to factors such as small-molecule drugs are simple, well-defined, and easy to characterize, Due to these features, they can quickly enter cells, affect molecules, and cause cancer cells to die and Increasing Number of Start-Ups and New Entrants in the Small-Molecule Drugs.
Which is the leading type of companies that use drug discovery services?
The drug discovery services market by drug type segment is broadly categorized into Tier 1, 2, and 3 companies. In 2019, Tier 1 companies commanded the largest share of the drug discovery services market. This is primarily attributed to the high capability of these companies to spend on R&D activities, long term vision to come up with new and novel drugs and maintaining a large pipeline of drugs.
Who are the key players operating in the drug discovery services market?
The prominent players operating in drug discovery services market include Laboratory Corporation of America Holdings (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Thermo Fisher Scientific, Inc. (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), and Selvita S.A. (Poland) among others.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 19)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 22)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.2 Market Size Estimation
2.2.1 Market Size Estimation: Bottom-Up Approach
2.2.2 Market Size Estimation: Top-Down Approach
2.2.3 Growth Forecast
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. - 29)
4 Premium Insights (Page No. - 33)
4.1 Drug Discovery Services Market Overview
4.2 North America: Market, By Drug Type & Country (2020)
4.3 Market: Geographic Growth Opportunities
5 Market Overview (Page No. - 36)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing R&D Expenditure in the Pharmaceutical & Biopharmaceutical Industry
5.2.1.2 Increasing Demand for Outsourcing Analytical Testing and Clinical Trial Services
5.2.1.3 Initiatives for Research on Rare Diseases and Orphan Drugs
5.2.1.4 Focus on Drug Discovery
5.2.2 Restraints
5.2.2.1 High Cost of Drug Discovery and Development
5.2.2.2 Stringent Regulations Governing Drug Discovery and Animal Usage
5.2.3 Opportunities
5.2.3.1 Growth in the Biologics Market
5.2.3.2 Patent Expiries
5.2.3.3 Emerging Markets
5.2.4 Trends
5.2.4.1 Growing Adoption of Artificial Intelligence-Based Tools for Drug Discovery
6 Drug Discovery Services Market, By Process (Page No. - 47)
6.1 Introduction
6.2 Target Selection
6.2.1 Increasing Demand for Personalized Medicine to Support the Growth of This Market
6.3 Target Validation
6.3.1 Rising Number of Drug Discovery Research Activities to Support Market Growth
6.4 Hit-To-Lead Identification
6.4.1 Hit-To-Lead Identification is the Largest Process Segment in the Market
6.5 Lead Optimization
6.5.1 Lead Optimization Requires State-Of-The-Art Informatics Systems to Facilitate Transparent Presentation and Analysis
6.6 Candidate Validation
6.6.1 Candidate Validation Segment to Grow at a High CAGR During the Forecast Period
7 Drug Discovery Services Market, By Type (Page No. - 53)
7.1 Introduction
7.2 Medicinal Chemistry Services
7.2.1 Wide Applications of Medicinal Chemistry in Drug Discovery are a Major Factor Driving Market Growth
7.3 Biology Services
7.3.1 Restrictions on the Usage of Animals in Research Activities May Limit Market Growth
7.4 Drug Metabolism & Pharmacokinetics
7.4.1 DMPK Studies are Employed at the Discovery, Candidate Selection, Investigational New Drug, and New Drug Application Stages
8 Drug Discovery Services Market, By Drug Type (Page No. - 57)
8.1 Introduction
8.2 Small-Molecule Drugs
8.2.1 Increasing Number of Start-Ups and New Entrants in the Small-Molecule Drugs Segment Will Drive the Growth of This Market During the Forecast Period
8.3 Biologic Drugs
8.3.1 High Set-Up Costs of the Instruments Required for Biologic Drug Manufacturing May Limit Market Growth to a Certain Extent
9 Drug Discovery Services Market, By Therapeutic Area (Page No. - 61)
9.1 Introduction
9.2 Oncology
9.2.1 High and Growing Number of Research Studies on Cancer Therapeutics to Support Market Growth
9.3 Neurology
9.3.1 Increasing Number of Patients Suffering From Neurological Disorders is Driving Market Growth
9.4 Infectious and Immune System Diseases
9.4.1 Emergence of New Infectious Diseases to Drive Market Growth
9.5 Digestive System Diseases
9.5.1 as There is a Huge Population Seeking Effective Remedies for Digestive Diseases, Pharmaceutical Companies are Investing Significantly in R&D for the Development of Innovative Drugs
9.6 Cardiovascular Diseases
9.6.1 High Global Burden of Cardiovascular Diseases has Increased the Focus on Developing Effective Drugs
9.7 Other Therapeutic Areas
10 Drug Discovery Services Market, By Company Type (Page No. - 70)
10.1 Introduction
10.2 Tier 1 Pharmaceutical Companies
10.3 Tier 2 Pharmaceutical Companies
10.4 Tier 3 Pharmaceutical Companies
11 Drug Discovery Services Market, By Region (Page No. - 73)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 Availability of Advanced R&D Infrastructure has Driven the Growth of the US Market
11.2.2 Canada
11.2.2.1 Preference of Pharmaceutical Companies to Conduct Clinical Trials in Canada to Support Market Growth
11.3 Europe
11.3.1 Germany
11.3.1.1 Government Support and Flexible Labor Laws are Driving the Growth of the German Market
11.3.2 UK
11.3.2.1 Investment By Pharmaceutical Sponsors in the UK for Drug Discovery Services to Support Market Growth
11.3.3 France
11.3.3.1 High Number of Oncology Clinical Trials in France to Drive Market Growth
11.3.4 Italy
11.3.4.1 High Number of Clinical Trials and the Low Drug Approval Time are the Major Factors Driving Market Growth
11.3.5 Spain
11.3.5.1 Short Study Start-Up Times and Rising R&D Expenditure to Boost the Growth of the Spanish Market
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.1.1 Low Cost of Clinical Trials and Large Pharmaceutical R&D Footprint in China to Drive Market Growth
11.4.2 India
11.4.2.1 Low-Cost Services and Availability of Skilled Workforce to Support Market Growth in India
11.4.3 Japan
11.4.3.1 Government Initiatives for Drug Innovation to Support Market Growth in Japan
11.4.4 Rest of Asia Pacific
11.5 Rest of the World
12 Competitive Landscape (Page No. - 117)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Partnerships, Agreements, and Collaborations
12.3.2 Service Launches
12.3.3 Mergers & Acquisitions
12.3.4 Expansions
12.4 Competitive Leadership Mapping
12.4.1 Visionary Leaders
12.4.2 Innovators
12.4.3 Dynamic Differentiators
12.4.4 Emerging Companies
13 Company Profiles (Page No. - 122)
13.1 Laboratory Corporation of America Holdings
13.1.1 Business Overview
13.1.2 Services Offered
13.1.3 Recent Developments
13.2 Eurofins Scientific Se
13.2.1 Business Overview
13.2.2 Services Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.3 Charles River Laboratories International
13.3.1 Business Overview
13.3.2 Services Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Evotec SE
13.4.1 Business Overview
13.4.2 Services Offered
13.4.3 Recent Developments
13.5 Thermo Fisher Scientific
13.5.1 Business Overview
13.5.2 Services Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Albany Molecular Research, Inc.
13.6.1 Business Overview
13.6.2 Services Offered
13.6.3 Recent Developments
13.7 Syngene International Limited
13.7.1 Business Overview
13.7.2 Services Offered
13.7.3 Recent Developments
13.8 Jubilant Lifesciences
13.8.1 Business Overview
13.8.2 Services Offered
13.8.3 Recent Developments
13.9 Genscript Biotech Corporation
13.9.1 Business Overview
13.9.2 Services Offered
13.9.3 Recent Developments
13.10 Piramal Enterprises Limited
13.10.1 Business Overview
13.10.2 Services Offered
13.10.3 Recent Developments
13.11 Selvita S.A.
13.11.1 Business Overview
13.11.2 Services Offered
13.11.3 Recent Developments
13.12 Aurigene Discovery Technologies (A Subsidiary of Dr. Reddy’s Laboratories)
13.12.1 Business Overview
13.12.2 Services Offered
13.12.3 Recent Developments
13.13 Domainex Ltd.
13.13.1 Business Overview
13.13.2 Services Offered
13.13.3 Recent Developments
13.14 WuXi AppTec
13.14.1 Business Overview
13.14.2 Services Offered
13.14.3 Recent Developments
13.15 Chempartner Co., Ltd.
13.15.1 Business Overview
13.15.2 Services Offered
13.15.3 Recent Developments
13.16 Frontage Holdings
13.16.1 Business Overview
13.16.2 Services Offered
13.16.3 Recent Developments
13.17 Pharmaceutical Product Development, LLC
13.17.1 Business Overview
13.17.2 Services Offered
13.17.3 Recent Developments
13.18 Shanghai Medicilon, Inc.
13.19 TCG Lifesciences Pvt. Limited
13.20 Viva Biotech (Shanghai) Ltd.
14 Appendix (Page No. - 161)
14.1 Discussion Guide
14.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.3 Available Customizations
14.4 Related Reports
14.5 Author Details
List of Tables (111 Tablese)
Table 1 Drug Discovery Process Overview
Table 2 Research Projects Funded By the Irdirc
Table 3 Average Cost of Drugs Approved Per Year, 2004–2013
Table 4 Drug Discovery Services Market, By Process, 2018–2025 (USD Million)
Table 5 Market for Target Selection, By Region, 2018–2025 (USD Million)
Table 6 Advantages and Disadvantages of Sirna
Table 7 Market for Target Validation, By Region, 2018–2025 (USD Million)
Table 8 Market for Hit-To-Lead Identification, By Region, 2018–2025 (USD Million)
Table 9 Market for Lead Optimization, By Region, 2018–2025 (USD Million)
Table 10 Market for Candidate Validation, By Region, 2018–2025 (USD Million)
Table 11 Market, By Type, 2018–2025 (USD Million)
Table 12 Medicinal Chemistry Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 13 Biology Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 14 DMPK Drug Discovery Services Market, By Region, 2018–2025 (USD Million)
Table 15 Market, By Drug Type, 2018–2025 (USD Million)
Table 16 Market for Small-Molecule Drugs, By Region, 2018–2025 (USD Million)
Table 17 Market for Biologic Drugs, By Region, 2018–2025 (USD Million)
Table 18 Global Number of Clinical Trials, By Therapeutic Area (As of October 2019)
Table 19 Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 20 Market for Oncology, By Region, 2018–2025 (USD Million)
Table 21 Market for Neurology, By Region, 2018–2025 (USD Million)
Table 22 Market for Infectious and Immune System Diseases, By Region, 2018–2025 (USD Million)
Table 23 Market for Digestive System Diseases, By Region, 2018–2025 (USD Million)
Table 24 Market for Cardiovascular Diseases, By Region, 2018–2025 (USD Million)
Table 25 Market for Other Therapeutic Areas, By Region, 2018–2025 (USD Million)
Table 26 Market, By Company Type, 2018–2025 (USD Million)
Table 27 Market for Tier 1 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 28 Market for Tier 2 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 29 Market for Tier 3 Pharmaceutical Companies, By Region, 2018–2025 (USD Million)
Table 30 Market, By Region, 2018–2025 (USD Million)
Table 31 North America: Market, By Country, 2018–2025 (USD Million)
Table 32 North America: Market, By Process, 2018–2025 (USD Million)
Table 33 North America: Market, By Type, 2018–2025 (USD Million)
Table 34 North America: Drug Discovery Services Market, By Drug Type, 2018–2025 (USD Million)
Table 35 North America: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 36 North America: Market, By Company Type, 2018–2025 (USD Million)
Table 37 Number of Clinical Trials Started in the US, By Company, 2017
Table 38 US: Market, By Process, 2018–2025 (USD Million)
Table 39 US: Market, By Type, 2018–2025 (USD Million)
Table 40 US: Market, By Drug Type, 2018–2025 (USD Million)
Table 41 US: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 42 Number of Active Clinical Trials in Canada, By Condition (2019)
Table 43 Number of Active Clinical Trials in Canada, By Company, 2017
Table 44 Canada: Market, By Process, 2018–2025 (USD Million)
Table 45 Canada: Market, By Type, 2018–2025 (USD Million)
Table 46 Canada: Market, By Drug Type, 2018–2025 (USD Million)
Table 47 Canada: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 48 Europe: Market, By Country, 2018–2025 (USD Million)
Table 49 Europe: Market, By Process, 2018–2025 (USD Million)
Table 50 Europe: Market, By Type, 2018–2025 (USD Million)
Table 51 Europe: Market, By Drug Type, 2018–2025 (USD Million)
Table 52 Europe: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 53 Europe: Market, By Company Type, 2018–2025 (USD Million)
Table 54 Germany: Market, By Process, 2018–2025 (USD Million)
Table 55 Germany: Market, By Type, 2018–2025 (USD Million)
Table 56 Germany: Market, By Drug Type, 2018–2025 (USD Million)
Table 57 Germany: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 58 UK: Drug Discovery Services Market, By Process, 2018–2025 (USD Million)
Table 59 UK: Market, By Type, 2018–2025 (USD Million)
Table 60 UK: Market, By Drug Type, 2018–2025 (USD Million)
Table 61 UK: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 62 Number of Clinical Trials Started in France, By Company, 2017
Table 63 France: Market, By Process, 2018–2025 (USD Million)
Table 64 France: Market, By Type, 2018–2025 (USD Million)
Table 65 France: Market, By Drug Type, 2018–2025 (USD Million)
Table 66 France: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 67 Number of Clinical Trials Started in Italy, By Company, 2017
Table 68 Italy: Market, By Process, 2018–2025 (USD Million)
Table 69 Italy: Market, By Type, 2018–2025 (USD Million)
Table 70 Italy: Market, By Drug Type, 2018–2025 (USD Million)
Table 71 Italy: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 72 Spain: Market, By Process, 2018–2025 (USD Million)
Table 73 Spain: Market, By Type, 2018–2025 (USD Million)
Table 74 Spain: Market, By Drug Type, 2018–2025 (USD Million)
Table 75 Spain: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 76 RoE: Market, By Process, 2018–2025 (USD Million)
Table 77 RoE: Market, By Type, 2018–2025 (USD Million)
Table 78 RoE: Market, By Drug Type, 2018–2025 (USD Million)
Table 79 RoE: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 80 Total Number of Clinical Trials in APAC, By Therapeutic Area, 2017
Table 81 APAC: Market, By Country, 2018–2025 (USD Million)
Table 82 APAC: Market, By Process, 2018–2025 (USD Million)
Table 83 APAC: Market, By Type, 2018–2025 (USD Million)
Table 84 APAC: Market, By Drug Type, 2018–2025 (USD Million)
Table 85 APAC: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 86 APAC: Market, By Company Type, 2018–2025 (USD Million)
Table 87 China: Market, By Process, 2018–2025 (USD Million)
Table 88 China: Market, By Type, 2018–2025 (USD Million)
Table 89 China: Drug Discovery Services Market, By Drug Type, 2018–2025 (USD Million)
Table 90 China: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 91 India: Market, By Process, 2018–2025 (USD Million)
Table 92 India: Market, By Type, 2018–2025 (USD Million)
Table 93 India: Market, By Drug Type, 2018–2025 (USD Million)
Table 94 India: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 95 Japan: Market, By Process, 2018–2025 (USD Million)
Table 96 Japan: Market, By Type, 2018–2025 (USD Million)
Table 97 Japan: Market, By Drug Type, 2018–2025 (USD Million)
Table 98 Japan: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 99 RoAPAC: Market, By Process, 2018–2025 (USD Million)
Table 100 RoAPAC: Market, By Type, 2018–2025 (USD Million)
Table 101 RoAPAC: Market, By Drug Type, 2018–2025 (USD Million)
Table 102 RoAPAC: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 103 RoW: Market, By Process, 2018–2025 (USD Million)
Table 104 RoW: Market, By Type, 2018–2025 (USD Million)
Table 105 RoW: Market, By Drug Type, 2018–2025 (USD Million)
Table 106 RoW: Market, By Therapeutic Area, 2018–2025 (USD Million)
Table 107 RoW: Market, By Company Type, 2018–2025 (USD Million)
Table 108 Partnerships, Agreements, and Collaborations (2017–2019)
Table 109 Service Launches (2017–2019)
Table 110 Mergers & Acquisitions (2017–2019)
Table 111 Expansions (2017–2019)
List of Figures (39 Figures)
Figure 1 Drug Discovery Services Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Process, 2020 Vs. 2025 (USD Million)
Figure 8 Market, By Type, 2020 Vs. 2025 (USD Million)
Figure 9 Market, By Drug Type, 2020 Vs. 2025 (USD Million)
Figure 10 Market, By Therapeutic Area, 2020 Vs. 2025 (USD Million)
Figure 11 Market, By Region, 2020 Vs. 2025 (USD Million)
Figure 12 Increasing R&D Expenditure in the Pharmaceutical & Biotechnology Industry to Drive Market Growth
Figure 13 Small-Molecule Drugs to Account for the Largest Share of the North American Market in 2020
Figure 14 China to Register the Highest Growth in the Drug Discovery Services Market During the Forecast Period
Figure 15 Market: Drivers, Restraints, and Opportunities
Figure 16 R&D Spending of Phrma Member Companies, 2001–2017 (USD Billion)
Figure 17 Active Pharmaceutical Pipeline, January 2009–January 2019
Figure 18 Number of Orphan Indications Approved in the US (2010–2017)
Figure 19 Number of Registered Studies (2005–2017)
Figure 20 Average Cost to Develop One New Approved Drug—Including the Cost of Failures
Figure 21 R&D Pipeline, By Therapy Group, 2018 & 2019
Figure 22 Total Number of Clinical Trials for Oncology, By Region (As of December 2019)
Figure 23 Total Number of Clinical Trials: Global Vs. North America
Figure 24 North America: Market Snapshot
Figure 25 US: Pipeline Split of Pharmaceutical and Biotechnology Companies, By Phase (January 2019)
Figure 26 UK: Pharmaceutical R&D Expenditure, 2013–2017
Figure 27 Spain: Pharmaceutical R&D Expenditure, 2011–2017
Figure 28 APAC: Market Snapshot
Figure 29 Market Share (2018)
Figure 30 Global Market: Competitive Leadership Mapping (2018)
Figure 31 Labcorp: Company Snapshot (2018)
Figure 32 Eurofins Scientific Se: Company Snapshot (2018)
Figure 33 Charles River Laboratories International: Company Snapshot (2018)
Figure 34 Evotec SE: Company Snapshot (2018)
Figure 35 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 36 Syngene: Company Snapshot (2018)
Figure 37 Jubilant Lifesciences: Company Snapshot (2018)
Figure 38 Genscript Biotech Corporation: Company Snapshot (2018)
Figure 39 Piramal Enterprises Limited: Company Snapshot (2018)
The study involved four major activities in estimating the current size of the drug discovery services market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative data. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. Other MnM proprietary reports were also referred to estimate the market size. These methods were also used extensively to determine the extent of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares split, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the whole market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the drug discovery services industry.
Report Objectives
- To define, describe, and forecast the drug discovery services market based on process, type, drug type, therapeutic area, company type, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and trends)
- To strategically analyze micro-markets for individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders operating in the market
- To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, and Rest of the World.
- To profile the key players and comprehensively analyze their services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as service launches, partnerships, collaborations, agreements, expansions, and acquisitions in the market.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Company Information: Detailed analysis and profiling of additional market players (up to 5)
- Further Split of The Drug Discovery Services Market For LATAM: Market size and growth rate estimates for Brazil, Mexico, and Argentina
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Drug Discovery Services Market